Leveragen has collaborated with Daiichi Sankyo to support research efforts in advanced biologics.

Under the collaboration, Daiichi Sankyo will work with Leveragen to apply Leveragen’s in-vivo antibody discovery capabilities in support of selected research programmes. The collaboration reflects a shared interest in exploring innovative discovery approaches that may enable the generation and evaluation of antibody-based biologics across multiple therapeutic areas.

“We are pleased to collaborate with Daiichi Sankyo, a global leader in antibody therapeutics with deep scientific expertise and a strong commitment to innovation. This collaboration reflects growing interest in next-generation in-vivo discovery platforms and their potential to support diverse biologic research efforts. We look forward to working together to advance new discovery programmes,” said Dr Weisheng Chen, Founder and Chief Executive Officer (CEO), Leveragen.

The collaboration further supports Leveragen’s strategy of working with pharmaceutical and biotechnology companies to apply its in-vivo discovery platforms in early-stage research and pre-clinical development.